MARK2 and acute myeloid leukemia: First, as expected we observed enrichment of vascular endothelial growth factor receptor FLT1 in ccRCC,24 receptor tyrosine kinases MET and KIT (CD117) in pRCC and chRCC/RO, respectively, and serine threonine kinase MYLK in AML (Figures 3A and 3B; Table S6).